FORGOT YOUR DETAILS?

The UK biopharma research
& development Summit

10 OCT 2018

ALPHABETA, 14-18 FINSBURY SQUARE,
LONDON EC2A 1BR

from

hosted by

moderated by

The panels will be recorded and broadcast through Endpoints News and our related summit sponsors.

JOIN US IN LONDON

The Golden Triangle in the UK is undergoing a major transformation as world-class scientific talent intermixes with a growing range of investors to create the next generation of drug developers in the UK. This October, Endpoints News will be bringing the biopharma community together for a special, half-day summit to address some of the most critical issues facing the country's drug development industry. And we'll be bringing together some of the top players in their fields to discuss financing, ROI and innovation and the exploding cancer drug development field.

PANELISTS

KATE BINGHAM

Managing Partner
SV Health Investors

DAVID GRAINGER

Co-founder, Chief Scientific Advisor
Medicxi

MENE PANGALOS

Executive VP of Innovative Medicines and Early Development Biotech Unit
AstraZeneca

NOOMAN HAQUE

Managing Director of Life Sciences and Healthcare
Silicon Valley Bank

MIKE REA

CEO
IDEA Pharma

JACKIE HUNTER

CEO
BenevolentBIO

JOHN POTTAGE

CSO and CMO
ViiV Healthcare

MALCOLM WEIR

Chief R&D Officer
SoseiHeptares

NIALL MARTIN

CEO
Artios

JOHN CARROLL

Founder & Editor
Endpoints News

GENGHIS LLOYD-HARRIS

Partner
Abingworth

DAVID CHISWELL

CEO
Kymab Ltd

NATALIE MOUNT

CSO
GammaDelta

AGENDA

13:00 - 13:15

WELCOME, OPENING REMARKS

13:15 - 14:15

Financing the next stage of drug development for UK biotech

The last year has seen an explosion of new biotech funding sources around the world. Extremely well connected Chinese investors are bursting onto the scene while traditional VCs enjoy strong support from institutional investors. Alternative financing strategies, meanwhile, have never been more popular. How is the UK’s golden triangle faring in the global context? Will Nasdaq remain the go-to spot to IPO, or will that shift to Hong Kong now? Will London’s market matter? Where, exactly, are we headed?

14:30 - 15:30

ROI AND INNOVATION IN DRUG DEVELOPMENT: WHAT ARE BIG AND LITTLE BIOPHARMAS DOING TO CHANGE THE EQUATION?

To hear the experts tell it, the ROI on drug development at Big Pharma has been falling for the past decade, and may well head into negative terrain soon. The implications for biotech are huge. Will smaller companies become the sole engine of early-stage innovation? Can Big Pharma save itself from poor productivity records, as evident in Europe as well as the US? What’s happening here and what new technologies — like AI — will play a key role in determining the future? Let's also not forget the role the current pricing debate in the US will play in determining the winners and losers of the future.

15:45 - 16:45

THE UK CANCER DRUG PIPELINE: INNOVATION IN AN ERA OF RAPID TECH PROLIFERATION

UK biotechs are well known for offering some of the most compelling, cutting-edge oncology development programs in the industry. We’ll talk to some of the leaders in the field, looking at the challenges of advancing new cancer drugs at a time hot targets in oncology are being overrun by rival therapies in Europe, the US and China. What will it take to remain out front? Is commoditization a real threat? Should cancer drug trials be restructured as patients become harder to recruit? Which trends present the highest hurdles, and the greatest opportunities?

17:00 - 18:00

Beer & wine mixer

sponsors

SPONSORSHIP PACKAGES AVAILABLE

Mike Peck - VP, Partnerships at Endpoints News - mike@endpointsnews.com

TOP